1 insider bought €18k of shares over the last 90 days, the latest filed 17 Sept 2026.
This page follows insider dealings at NUZ as filed with ASX, a company from the Health Care sector. From 18 October 2025 to 18 October 2026, the disclosure feed for NUZ logged 3 filings by 3 insiders.
On the market, 2 insiders bought (2 purchases totalling €39k) while 1 insider sold (1 sale). No amount is published for 1 filing, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. At €21k, the purchase published on 30 June 2026 by Marcus Hughes is the largest of the period (0.055% of market cap). Those buying include 2 senior executives.
For context, the typical company on the same exchange (median of 2,530 companies) published 3 filings over the same period, against 3 filings here. Over the whole record (from 2026), the tally stands at 2 purchases and 1 sale.
The latest purchase dates back some time: it was published 31 days ago, on 17 September 2026.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Source: insider filings from ASX. Past trades are no guide to future returns.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate NUZ Strong Buy (bullish), based on 1 analysts. Average price target: A$0.20.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended June 2025 · cache
3 of 3 declarations
NUZ is a company operating in the healthcare and pharmaceutical sector, listed on the XASX.
Purchases our model currently ranks for the recommendations list.
All recommendations